A role of phosphodiesterase-3B pathway in mediating leptin action on proopiomelanocortin and neurotensin neurons in the hypothalamus.
Leptin signaling in the hypothalamus is required for normal food intake and body weight homeostasis. Recent evidence suggests that besides the signal transducer and activator of transcription-3 (STAT3) pathway, several non-STAT3 pathways mediate leptin signaling in the hypothalamus. We have previously demonstrated that leptin stimulates phosphodiesterase-3B (PDE3B) activity in the hypothalamus, and PDE3 inhibitor cilostamide reverses anorectic and body weight reducing effects of leptin. To establish the physiological role of PDE3B signaling in the hypothalamus, we examined if leptin signaling through the PDE3B pathway is responsible for the activation of proopiomelanocortin (POMC) and neurotensin (NT) neurons, which are known to play a critical role in energy homeostasis. To this end, we assessed the effect of cilostamide on leptin-induced POMC and NT gene expression in the rat hypothalamus. Results showed that while central injection of leptin significantly increased both POMC and NT mRNA levels in the medial basal hypothalamus, cilostamide completely reversed this effect of leptin suggesting a PDE3B-activation dependent induction of POMC and NT gene expression by leptin. This result further suggests that the PDE3B pathway plays an important role in mediating leptin action in the hypothalamus.
Sahu
Abhiram
A
Department of Cell Biology and Physiology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA. asahu@pitt.edu
D000818:Animals; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3 / Q000378:metabolism*; D015870:Gene Expression; D007031:Hypothalamus / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*; D020738:Leptin / Q000378:metabolism*; D008297:Male; D008959:Models, Neurological; D009474:Neurons / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*; D009496:Neurotensin / Q000235:genetics / Q000378:metabolism*; D058987:Phosphodiesterase 3 Inhibitors; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D011333:Pro-Opiomelanocortin / Q000235:genetics / Q000378:metabolism*; D015363:Quinolones / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D015398:Signal Transduction
D020738:Leptin; D058987:Phosphodiesterase 3 Inhibitors; D010726:Phosphodiesterase Inhibitors; D015363:Quinolones; D012333:RNA, Messenger; D009496:Neurotensin; C021294:cilostamide; D011333:Pro-Opiomelanocortin; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3; C517294:Pde3b protein, rat
Cell Metab. 2009 Nov;10(5):343-54
19883613
Eur J Pharmacol. 1982 Jul 16;81(3):499-503
6811292
Peptides. 1987 Sep-Oct;8(5):921-6
2448757
Neuron. 2004 Jun 24;42(6):983-91
15207242
J Clin Invest. 2008 May;118(5):1796-805
18382766
Nature. 2000 Apr 6;404(6778):661-71
10766253
Mol Endocrinol. 2008 Mar;22(3):751-9
18096691
Nat Genet. 1996 Sep;14(1):95-7
8782827
J Biol Chem. 2000 May 12;275(19):14563-72
10799542
Proc Natl Acad Sci U S A. 2004 Nov 9;101(45):16064-9
15520383
Endocrinology. 2003 Sep;144(9):3789-98
12933650
Endocrinology. 2007 Jan;148(1):72-80
17023536
J Biol Chem. 1997 Mar 7;272(10):6093-6
9102398
Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8878-83
9238071
J Biol Chem. 1988 Apr 5;263(10):4963-8
2832414
Endocrinology. 1980 Jul;107(1):47-54
6991249
J Comp Neurol. 1998 Jun 15;395(4):535-47
9619505
Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4661-6
15070774
J Neurosci. 2001 Apr 1;21(7):2413-24
11264315
Diabetes. 2001 Feb;50(2):425-35
11272157
Endocrinology. 2003 May;144(5):2121-31
12697721
J Biol Chem. 1997 Dec 19;272(51):32686-95
9405487
Neurosci Lett. 2008 Aug 1;440(2):125-9
18562101
Nature. 2003 Feb 20;421(6925):856-9
12594516
Pharmacol Biochem Behav. 1983 Jan;18(1):19-23
6131439
J Neuroendocrinol. 2005 Nov;17(11):720-6
16219000
Nature. 2004 Apr 1;428(6982):569-74
15058305
Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8374-8
8710878
Trends Endocrinol Metab. 1999 Aug;10(6):211-216
10407394
J Neuroendocrinol. 1992 Feb;4(1):79-89
21554581
Nature. 1998 Oct 22;395(6704):763-70
9796811
Front Neuroendocrinol. 2003 Dec;24(4):225-53
14726256
Nature. 2001 Oct 25;413(6858):794-5
11677594
J Clin Invest. 2001 Oct;108(8):1113-21
11602618
Mol Endocrinol. 1997 Apr;11(4):393-9
9092791
Cell Metab. 2008 Apr;7(4):291-301
18396135
Brain Res. 2001 Jan 12;888(2):343-347
11150496
Am J Physiol Regul Integr Comp Physiol. 2004 Jan;286(1):R143-50
12958061
J Biol Chem. 2001 Feb 16;276(7):4747-55
11085989
Science. 2006 May 12;312(5775):927-30
16690869
Neuron. 1999 Aug;23(4):775-86
10482243
J Neuroendocrinol. 2002 Oct;14(10):796-804
12372004
Nature. 1994 Dec 1;372(6505):425-32
7984236
J Clin Endocrinol Metab. 1999 Feb;84(2):711-7
10022442
Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6231-5
8692797
Nat Med. 2006 May;12(5):534-40
16604086
Peptides. 2004 Dec;25(12):2135-8
15572202
J Neurosci. 2005 Oct 12;25(41):9497-506
16221860
Nat Neurosci. 2002 Aug;5(8):727-8
12101402
J Clin Invest. 2000 Jun;105(12):1827-32
10862798
Endocrinology. 1998 Feb;139(2):795-8
9449656
Methods Mol Biol. 2000;153:219-30
10957996
Peptides. 1983 Jul-Aug;4(4):493-500
6685868